Cel-Sci Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating

Cel-Sci (CVM) saw an improvement to its Relative Strength Rating on Thursday, rising from 79 to 87. An over-80 RS Rating makes Cel-Sci stock a potential candidate for your watchlist.


When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength.

This proprietary rating measures market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock’s price performance over the trailing 52 weeks matches up against other publicly traded companies.

History reveals that the top-performing stocks typically have an RS Rating north of 80 in the early stages of their moves.

Looking For Winning Stocks? Try This Simple Routine

Is Cel-Sci Stock A Buy?

Cel-Sci stock has moved more than 5% past an 18.10 entry in a third-stage consolidation, meaning it’s now out of a proper buy range. Look for Cel-Sci stock to offer a new buying opportunity like a three-weeks-tight pattern or a pullback to the 50-day or 10-week line.

The maker of immunotherapy products reported a 12% earnings contraction in its most recent report. Revenue shrank by 100%.

Cel-Sci stock earns the No. 155 rank among its peers in the Medical-Biomed/Biotech industry group. Alexion Pharmaceuticals (ALXN) and Maravai Lifesciences (MRVI) are also among the group’s highest-rated stocks.


Find The Best Stocks To Buy Using IBD’s Proprietary Watchlists

MarketSmith’s Tools Can Help The Individual Investor

IBD Live: A New Tool For Daily Stock Market Analysis

Profit From Short-Term Trends With SwingTrader

IBD Stock Rating Upgrades: Rising Relative Strength

Most Related Links :
newsbinding Governmental News Finance News

Source link

Back to top button